Effect of montelukast on the concentration of inflammatory mediators in the murine gouty arthritis model

Article Spanish OPEN
Ponce, Loida; Bermúdez, Mariangélica; Miranda, Jorgelin; Verzura, Julie; Tovar, Robert; Corado, José;
(2016)
  • Publisher: Universidad de Carabobo
  • Subject: inflammatory mediators | experimental model of gouty arthritis | montelukast | Modelo experimental de artritis gotosa | mediadores inflamatorios

El tratamiento de la artritis gotosa controla parcialmente la enfermedad con efectos secundarios importantes. El montelukast es un antagonista selectivo de los receptores de leucotrienos LTD4, útil en el tratamiento de rinitis alérgica y asma bronquial. Investigaciones ... View more
  • References (30)
    30 references, page 1 of 3

    10. Pérez S. Inmunopatogenia de la gota. Rev Chil Reumatol 2008; 24 (3): 133-137.

    11. Perez F, Calabozo M, Piojoan J, Herre A, Rubial A. Effect of urate- lowering therapy on the velocity of size reduction of trophy in chronic gout. Arthritis Rheum 2002; 47 (4): 356-360.

    12. Aherm M, Reid C, Gordon T, McCredie M, Brooks PM, Jones M: Does Colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987; 17:301-304.

    13. Dalbet h N, Lauterio T, Wolfe H. Mechanism of action of colchicine in the treatment of gout. Clin Ther 2014; 36 (10):1465-1479.

    14. Sutaria S, Katbamna R, Underwood M: Effectiveness of interventions for the treatment of acute and prevention of recurrent gout- a systematic review. Rheumatology 2006; 45:1422-1431.

    15. Janssens H, Janssen M, van de Lisdonk E, van Riel P, van Weel C: Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial. Lancet: 2008; 371: 1854-1860.

    16. Robinson P, Horsburgh S. Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities. Maturitas 2014; 78(4):245-251.

    17. Riccioni G, Di Ilio C, Conti P, Theoharides T, D'orazio N. Advances in therapy with antileukotriene drugs. Ann Clin Lab Sci 2004; 34 (4):379-387.

    18. Jones T, Labelle M, Chamion E, Charette L, Evans J, FordHutchinson AW, et al., Pharmacology of montelukast sodium (Singulair tm), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 1995; 73(2):191-201.

    34. Anderson R, Theron AJ, Gravett CM, Steel HC, Tintiger GR, Feldman C. Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism. Br J Pharmacol 2009; 156 (1):105-115.

  • Metrics
Share - Bookmark